These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 31981446)
1. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446 [TBL] [Abstract][Full Text] [Related]
2. Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer. Li H; Zhu YZ; Xu L; Han T; Luan J; Li X; Liu Y; Wang Z; Liu Q; Kong X; Zou C; Su L; Hou Y; Chen X; Chen L; Wang R; Xu Z; Zhao M J Exp Clin Cancer Res; 2024 Apr; 43(1):129. PubMed ID: 38685125 [TBL] [Abstract][Full Text] [Related]
3. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678 [TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584 [TBL] [Abstract][Full Text] [Related]
6. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266 [TBL] [Abstract][Full Text] [Related]
10. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757 [TBL] [Abstract][Full Text] [Related]
11. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer. Yu J; Yang M; Peng T; Liu Y; Cao Y Sci Rep; 2023 Nov; 13(1):18791. PubMed ID: 37914786 [TBL] [Abstract][Full Text] [Related]
13. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568 [TBL] [Abstract][Full Text] [Related]
16. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence. Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer. Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K Oncology; 2020; 98(7):501-511. PubMed ID: 32380498 [TBL] [Abstract][Full Text] [Related]
19. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045 [TBL] [Abstract][Full Text] [Related]
20. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]